The Hypoxic Microenvironment Induces Stearoyl-CoA Desaturase-1 Overexpression and Lipidomic Profile Changes in Clear Cell Renal Cell Carcinoma

• Published in: Cancers Vol. 13; no. 12; p. 2962
• Main Authors: Melana, Juan Pablo, Mignolli, Francesco, Stoyanoff, Tania, Aguirre, María V., Balboa, María A., Balsinde, Jesús, Rodríguez, Juan Pablo
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 13.06.2021; MDPI
• Subjects: Apoptosis; Cell growth; Cell proliferation; Chromatography; Clear cell-type renal cell carcinoma; Desaturase; Fatty acids; Flow cytometry; Hypoxia; Kidney cancer; Lipid composition; Lipid metabolism; Lipids; Metabolism; Metabolites; Microenvironments; Microscopy; Oleic acid; Phenotypes; Software; Stearoyl-CoA desaturase; Therapeutic applications; Tumor cells; Tumors; United States > US; Argentina; Spain
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13122962

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma (RCC). It is characterized by a high cell proliferation and the ability to store lipids. Previous studies have demonstrated the overexpression of enzymes associated with lipid metabolism, including stearoyl-CoA desaturase-1 (SCD-1), which increases the concentration of unsaturated fatty acids in tumor cells. In this work, we studied the expression of SCD-1 in primary ccRCC tumors, as well as in cell lines, to determine its influence on the tumor lipid composition and its role in cell proliferation. The lipidomic analyses of patient tumors showed that oleic acid (18:1n-9) is one of the major fatty acids, and it is particularly abundant in the neutral lipid fraction of the tumor core. Using a ccRCC cell line model and in vitro-generated chemical hypoxia, we show that SCD-1 is highly upregulated (up to 200-fold), and this causes an increase in the cellular level of 18:1n-9, which, in turn, accumulates in the neutral lipid fraction. The pharmacological inhibition of SCD-1 blocks 18:1n-9 synthesis and compromises the proliferation. The addition of exogenous 18:1n-9 to the cells reverses the effects of SCD-1 inhibition on cell proliferation. These data reinforce the role of SCD-1 as a possible therapeutic target.